China Bictegravir 1611493-60-7 artifices et instructores

Bictegravir 1611493-60-7

Brevis descriptio:

API Nomen	Indicium	Innovator	Exitus patentibus Date (US)
Bictegravir 1611493-60-7	HIV-1 infectio	Gilead Sciences	19 Dec

Mitte ad nos inscriptio

Product Detail

Product Tags

Product SINGULA

Descriptio

Bictegravir nova est, potens inhibitor HIV-1 integrae cum IC50 7.5 nm.

in Vitro

Bictegravir (BIC) vetat trans- lationem actionem cum IC50 inter 7.5± 0.3 nM. Relativum ad suum inhibitionis trans- litus activitatem, Bictegravir multo infirmior est inhibitor of 3 ..-processing actio HIV-I IN, cum IC50 de 241±51 nM. Bictegravir auget cumulum 2-LTR circulorum ~5-plicarum relativum ad ludibrium tractatum imperium ac quantitatem productorum integrationis authenticae in cellulis infectis per 100-duplicem reducit. Bictegravir potenter vetat replicationem HIV-1 in utroque MT-2 et MT-4 cellularum cum EC50s 1.5 et 2.4 nM, respective. Bictegravir effectus antivirales potentes exhibet lymphocytes tum primarios CD4+ T et macrophages monocyto-deductum, cum EC50s 1.5.±0.3 nM et 6.6 "±4.1 nM, respective, quae cum valoribus in lineis T-cellulis habitis comparantur[1].

MCE independenter subtilitatem horum methodorum non confirmavit. Tantum referendi sunt.

NCT Number	Sponsor	Conditio	Satus Date	Phase
NCT03998176	Universitas Nebraska\|Gilead Sciences	HIV-1-infectio	October 9, 2019	Phase 4
NCT03789968	Thomas Jefferson University\|University of Maryland, College Park\| University Health in Indiana\|The Brooklyn Hospital Center\|University Illinois at Chicago\|Nova Southeastern University\|University of California, San Francisco	HIV+AIDS	Septembris 1, 2019
NCT04249037	University of Colorado, Denver\|Gilead Sciences	HIV+AIDS	Martii 1, 2020	Non Lorem
NCT04132674	Vancuverium Infectious Diseases Centre	Humana immunitas Virus I Infectio\|Drug Use	November 26, 2018	Phase 4
NCT04054089	Cristina Mussini Universitas Mutinensis et Regii Lepidi	HIV Infectiones	September 2019	Phase 4
NCT04155554	Azienda Ospedaliera Universitaria Senese \| Catholic University of the Holy Heart \| Ospedale Policlinico San Martino \|	HIV-1-infectio	die 29 mensis Ianuarii anno 2020	Phase 3
NCT02275065	Gilead Sciences	HIV-1 Infectio	October 2014	Phase 1
NCT03711253	Universitas Southern California	Acutus HIV Infectio	October 14, 2019	Phase 4
NCT02400307	Gilead Sciences	HIV	April 17, 2015	Phase 1
NCT03499483	Fenway Community Health	HIV Prevention	Die 24 mensis Ianuarii, 2019	Phase 4
NCT03502005	Mediterranei Research Group, Inc.\|Gilead Sciences	Virus immunis	Martii 1, 2018	Phase 4